Innovations in mRNA-Based Nanoparticle for the Treatment of Ocular Disorders: A Comprehensive Review.

IF 2.8 4区 医学 Q2 PHARMACOLOGY & PHARMACY
Krishana Kumar Sharma, Sumit Durgapal, Siddhant Jai Tyagi, Prakhar Varshney, Gajendra Kumar
{"title":"Innovations in mRNA-Based Nanoparticle for the Treatment of Ocular Disorders: A Comprehensive Review.","authors":"Krishana Kumar Sharma, Sumit Durgapal, Siddhant Jai Tyagi, Prakhar Varshney, Gajendra Kumar","doi":"10.2174/0113816128391408250804231522","DOIUrl":null,"url":null,"abstract":"<p><p>The eye, due to its complex anatomy and physiology, presents numerous barriers that restrict the access of drug molecules to the site of action for the maintenance of optimal concentration. Thus, limited drug bioavailability is one of the significant issues with commercially existing drug delivery systems in achieving overall therapeutic effectiveness. Recently, the field of ocular health and management has garnered much attention for the innovation of efficient nanotechnology approaches to overcome the constraints imposed by the intricate anatomy and physiology of the eye. Hypothesizing that the conjugation of mRNA-based therapies with the latest nano delivery systems can overcome these barriers, this review was designed to explore the outstanding potential of these approaches for the management of ocular disorders. With extensive investigations of current findings, the authors believe that such integrations present exciting opportunities to pave the way for the development of effective approaches for various ocular disorders such as uveitis, Leber congenital amaurosis, age-related macular degeneration, retinitis pigmentosa, and many more. Moreover, the approaches exploiting the combination of mRNA and nanotechnology offer effective solutions to address the limitations of currently available management strategies. This review presents various innovative mRNA-based nanotechnology approaches, their mechanisms, challenges, and prospects for further development, focusing on the immense potential of mRNA-based strategies to revolutionize the landscape of ocular therapeutics.</p>","PeriodicalId":10845,"journal":{"name":"Current pharmaceutical design","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical design","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113816128391408250804231522","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

The eye, due to its complex anatomy and physiology, presents numerous barriers that restrict the access of drug molecules to the site of action for the maintenance of optimal concentration. Thus, limited drug bioavailability is one of the significant issues with commercially existing drug delivery systems in achieving overall therapeutic effectiveness. Recently, the field of ocular health and management has garnered much attention for the innovation of efficient nanotechnology approaches to overcome the constraints imposed by the intricate anatomy and physiology of the eye. Hypothesizing that the conjugation of mRNA-based therapies with the latest nano delivery systems can overcome these barriers, this review was designed to explore the outstanding potential of these approaches for the management of ocular disorders. With extensive investigations of current findings, the authors believe that such integrations present exciting opportunities to pave the way for the development of effective approaches for various ocular disorders such as uveitis, Leber congenital amaurosis, age-related macular degeneration, retinitis pigmentosa, and many more. Moreover, the approaches exploiting the combination of mRNA and nanotechnology offer effective solutions to address the limitations of currently available management strategies. This review presents various innovative mRNA-based nanotechnology approaches, their mechanisms, challenges, and prospects for further development, focusing on the immense potential of mRNA-based strategies to revolutionize the landscape of ocular therapeutics.

基于mrna的纳米颗粒治疗眼部疾病的创新:综述
眼睛由于其复杂的解剖和生理结构,存在许多障碍,限制药物分子进入作用部位以维持最佳浓度。因此,有限的药物生物利用度是商业上现有的药物输送系统在实现整体治疗效果方面的重要问题之一。近年来,利用高效的纳米技术来克服眼睛复杂的解剖和生理结构所带来的限制,引起了眼健康和眼管理领域的广泛关注。假设基于mrna的疗法与最新的纳米递送系统结合可以克服这些障碍,本综述旨在探索这些方法在眼部疾病治疗中的突出潜力。通过对当前研究结果的广泛调查,作者认为,这种整合为开发各种眼部疾病(如葡萄膜炎、Leber先天性黑内障、年龄相关性黄斑变性、视网膜色素变性等)的有效方法提供了令人兴奋的机会。此外,利用mRNA和纳米技术相结合的方法为解决当前可用管理策略的局限性提供了有效的解决方案。本文综述了各种基于mrna的创新纳米技术方法及其机制、挑战和进一步发展的前景,重点介绍了基于mrna的策略在眼科治疗领域的巨大潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.30
自引率
0.00%
发文量
302
审稿时长
2 months
期刊介绍: Current Pharmaceutical Design publishes timely in-depth reviews and research articles from leading pharmaceutical researchers in the field, covering all aspects of current research in rational drug design. Each issue is devoted to a single major therapeutic area guest edited by an acknowledged authority in the field. Each thematic issue of Current Pharmaceutical Design covers all subject areas of major importance to modern drug design including: medicinal chemistry, pharmacology, drug targets and disease mechanism.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信